Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Numinus Wellness Inc T.NUMI

Alternate Symbol(s):  NUMIF

Healthcare
Numinus Wellness Inc. is a mental health care company. The Company focuses on advancing traditional and behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies. Its segments include Clinical research operations, Practitioner Training, Clinic network, and Corporate. Clinical research operations segment is focused on licensed psychedelic research and... see more

Recent & Breaking News (TSX:NUMI)

Numinus Adds Ayahuasca & San Pedro to Federal License for Psychedelic Research

PR Newswire March 9, 2022

The StockTalk Cannabis Report: Mar 4, 2022

Dave Jackson March 4, 2022

Psychedelics Stock Hits New Milestones Driven by Strategy & Experience

Stockhouse Editorial March 2, 2022

Numinus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders

PR Newswire February 28, 2022

Numinus to Participate in AAAS 2022 Annual Meeting on February 17-20, 2022

PR Newswire February 10, 2022

Numinus Appoints New Bioscience Advisors to Advance IP Development

PR Newswire February 1, 2022

Numinus Identified as a Licensed Psilocybin Supplier by Health Canada

PR Newswire January 27, 2022

Numinus Wellness Inc. Graduates to the OTCQX Best Market

PR Newswire January 26, 2022

Numinus to Participate in Citi's Psychedelic Drug Call Series on February 2, 2022

PR Newswire January 25, 2022

Numinus Wellness Inc. Reports Q1 2022 Results

PR Newswire January 20, 2022

Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical Trial

PR Newswire January 19, 2022

Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product

PR Newswire January 14, 2022

Numinus Announces Cancellation and Rescheduling of Annual General Meeting of Shareholders

PR Newswire January 13, 2022

Numinus Announces Q1 2022 Results Conference Call Update

PR Newswire January 7, 2022

Numinus to Host Q1 2022 Results Conference Call on January 13, 2022

PR Newswire January 5, 2022

Numinus Wellness Commends Health Canada on Special Access Programme Amendments to Restore Potential Access to Psychedelic Medicines

PR Newswire December 22, 2021

Numinus Wellness Inc. to commence trading on the TSX

Stockhouse Editorial December 16, 2021

Numinus Wellness Inc. to Commence Trading on the TSX on December 16, 2021

PR Newswire December 14, 2021

Numinus Wellness Inc. Reports Q4 and Year End 2021 Results

PR Newswire December 9, 2021

Numinus to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th

PR Newswire November 30, 2021